Real-World Insights From the LOGEX IMID Observatory: A Multicountry, Multiyear Analysis of Treatment Pathways and Healthcare Resource Utilization in Immune-Mediated Inflammatory Diseases
Author(s)
Jasper Deuring, PhD1, Menno Gaastra, MD PhD2, eric grossat, MsC3, Rodolfo Romero, MD PhD4, Jan Van Der Eijk, MsC5.
1LOGEX B.V., Amsterdam, Netherlands, 2noordwest Ziekenhuisgroep, Centrum Oosterwal, Alkmaar, Netherlands, 3Logex Healthcare Analytics, alboraya, Spain, 4Gregorio Marañón University General Hospital, Madrid, Spain, 5LOGEX BV, Amsterdam, Netherlands.
1LOGEX B.V., Amsterdam, Netherlands, 2noordwest Ziekenhuisgroep, Centrum Oosterwal, Alkmaar, Netherlands, 3Logex Healthcare Analytics, alboraya, Spain, 4Gregorio Marañón University General Hospital, Madrid, Spain, 5LOGEX BV, Amsterdam, Netherlands.
OBJECTIVES: To describe the structure, data capabilities, and clinical utility of the LOGEX IMID Observatory—a pan-European, initiative that leverages real-world data (RWD) to evaluate treatment patterns, healthcare resource utilization (HCRU), and patient outcomes across immune-mediated inflammatory diseases (IMIDs) in dermatology, rheumatology, and gastroenterology.
METHODS: The LOGEX IMID-Observatory integrates anonymized claims and medication prescription data from 5-10 hospitals per country across Spain, the United Kingdom, and the Netherlands. Data collection began in 2019 and is updated monthly with a maximum lag time of one quarter. The observatory captures longitudinal patient journeys, including treatment sequencing, switching, and duration, and visualizes treatment lines across indications. Participating hospitals contribute retrospective data without additional registration burden. Data access is governed by a secure, standardized protocol, enabling reuse for multiple research questions. HCRU metrics are calculated per patient and per treatment line, and benchmarking is enabled across institutions.
RESULTS: The observatory currently includes over 20 hospitals and continues to expand. It provides detailed insights into real-world treatment pathways for conditions such as psoriasis, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and psoriatic arthritis. Key findings include variability in time to advanced therapy, biosimilar uptake, and steroid use across countries and centers. Participating hospitals benefit from tailored dashboards, benchmarking reports, and scientific collaboration opportunities. Several peer-reviewed publications have already been generated using observatory data, demonstrating its value for both clinical and health economic research.
CONCLUSIONS: The LOGEX IMID-Observatory offers a scalable, efficient, and scientifically robust platform for understanding and improving the management of IMIDs across Europe. By combining multi-country RWD with advanced analytics and clinician engagement, it supports evidence-based decision-making, fosters cross-border collaboration, and enhances the quality and efficiency of care delivery. Acknowledgements Thank you to: Rodolfo Romero Pareja (Medical Subdirector), Ofelia Baniandres Rodriguez (Dermatology), Juan Carlos Nieto Gonzalez (Rheumatology) and Luis Menchen Viso (Gastroenterology), from the Gregorio Marañon Hospital, Madrid Spain
METHODS: The LOGEX IMID-Observatory integrates anonymized claims and medication prescription data from 5-10 hospitals per country across Spain, the United Kingdom, and the Netherlands. Data collection began in 2019 and is updated monthly with a maximum lag time of one quarter. The observatory captures longitudinal patient journeys, including treatment sequencing, switching, and duration, and visualizes treatment lines across indications. Participating hospitals contribute retrospective data without additional registration burden. Data access is governed by a secure, standardized protocol, enabling reuse for multiple research questions. HCRU metrics are calculated per patient and per treatment line, and benchmarking is enabled across institutions.
RESULTS: The observatory currently includes over 20 hospitals and continues to expand. It provides detailed insights into real-world treatment pathways for conditions such as psoriasis, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and psoriatic arthritis. Key findings include variability in time to advanced therapy, biosimilar uptake, and steroid use across countries and centers. Participating hospitals benefit from tailored dashboards, benchmarking reports, and scientific collaboration opportunities. Several peer-reviewed publications have already been generated using observatory data, demonstrating its value for both clinical and health economic research.
CONCLUSIONS: The LOGEX IMID-Observatory offers a scalable, efficient, and scientifically robust platform for understanding and improving the management of IMIDs across Europe. By combining multi-country RWD with advanced analytics and clinician engagement, it supports evidence-based decision-making, fosters cross-border collaboration, and enhances the quality and efficiency of care delivery. Acknowledgements Thank you to: Rodolfo Romero Pareja (Medical Subdirector), Ofelia Baniandres Rodriguez (Dermatology), Juan Carlos Nieto Gonzalez (Rheumatology) and Luis Menchen Viso (Gastroenterology), from the Gregorio Marañon Hospital, Madrid Spain
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
RWD145
Topic
Epidemiology & Public Health, Real World Data & Information Systems, Study Approaches
Topic Subcategory
Distributed Data & Research Networks
Disease
Biologics & Biosimilars, Gastrointestinal Disorders, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)